2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,800 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
July 24, 2023
Video
Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.
July 20, 2023
Video
Rami Komrokji, MD, shares the potential clinical implications of data from the phase 3 COMMANDS trial of luspatercept in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.
July 17, 2023
Video
Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.
July 17, 2023
Video
A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.
July 14, 2023
Video
Rami Komrokji, MD, discusses the clinical implications of the phase 3 COMMANDS trial in patients with very low–, low-, or intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.
July 14, 2023
Video
A broad view of the current treatment paradigm for relapsed/refractory follicular lymphoma and how the field has been evolving.
July 14, 2023
Video
Experts Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, reflect on recent updates to the treatment guidelines for patients with follicular lymphoma.
July 10, 2023
Video
Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
July 10, 2023
Video
Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
July 06, 2023
Video
George Simon, MD, FACP, FCCP, discusses findings from an FDA pooled analysis of PD-1/PD-L1 inhibitors with or without chemotherapy in patients with non–small cell lung cancer.
July 05, 2023
Video
Andrew S. Brohl, MD, discusses the safety and immunologic responses with intratumoral administration of Idx-Hu2.0 in patients with advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma.
July 05, 2023
Video
Danielle K. DePalo, MD, discusses findings from a study comparing first-line isolated limb infusion/perfusion vs immune checkpoint inhibitors and intratumoral therapy in patients with surgically unresectable melanoma in-transit metastases.
July 05, 2023
Article
A treatment regimen consisting of pepinemab plus trastuzumab and a dendritic cell vaccine, followed by autologous CD4-positive T cells, is under investigation in a phase 1 trial in patients with metastatic HER2-positive breast cancer.
July 03, 2023
Video
A brief review of data behind lisocabtagene maraleucel and its role as CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
July 03, 2023
Video
Shared insight on the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, with a focus on axicabtagene ciloleucel.
June 30, 2023
Video
Andreas Saltos, MD, discusses final results from a phase 2 trial of first-line pembrolizumab plus vorinostat in patients with metastatic non–small cell lung cancer.
June 29, 2023
Video
Bruna Pellini, MD, discusses the use of circulating tumor DNA monitoring to inform maintenance outcomes in patients with advanced non–small cell lung cancer treated with induction therapy with atezolizumab, carboplatin, and nab-paclitaxel.
June 27, 2023
Video
Damon R. Reed, MD, discusses a phase 2 study of fam-trastuzumab deruxtecan-nxki in adolescent and young adult patients with recurrent HER2-positive osteosarcoma.
June 26, 2023
Video
Rami Komrokji, MD, discusses key findings from an expanded analysis of the classification of patients with myelodysplastic syndromes.
June 26, 2023
Video
Panelists review data behind the combination of tafasitamab and lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.